Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
- Conditions
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 818
- Registration Number
- NCT04305496
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04087174
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT03997123
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 750
- Registration Number
- NCT03903835
- Locations
- 🇳🇴
Akershus Universitetssykehus, Lørenskog, Norway
🇧🇪OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪Ziekenhuis Oost-Limburg, Genk, Belgium
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Metastatic Triple-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Procedure: BiopsyOther: Quality-of-Life Assessment
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT03801369
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Conditions
- Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaStage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Multigated Acquisition Scan
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 286
- Registration Number
- NCT03660826
- Locations
- 🇺🇸
Huron Medical Center PC, Port Huron, Michigan, United States
🇺🇸Health Partners Inc, Minneapolis, Minnesota, United States
🇺🇸Monticello Cancer Center, Monticello, Minnesota, United States
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
- Conditions
- ER+ HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 396
- Registration Number
- NCT03616587
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
- Conditions
- Breast CancerProstate CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT03310541
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 1150
- Registration Number
- NCT03182634
- Locations
- 🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧Royal Marsden Hosital, Sutton, England, United Kingdom
🇬🇧Clatterbridge Cancer Centre, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.